Protein Kinase Inhibitors As Sensitizing Agents for Chemotherapy |
|
| Series edited by:
| Bonavida, Benjamin |
| Volume Editor:
| Chen, Zhe-Sheng (Jason)
Yang, Dong-Hua |
| Series title: | Issn Ser. |
| ISBN: | 978-0-12-812738-4 |
| Publication Date: | Nov 2018 |
| Publisher: | Elsevier Science & Technology Books
|
| Imprint: | Academic Press |
| Book Format: | Ebook |
| List Price: | Contact Supplier contact
Contact Supplier contact
Contact Supplier contact
|
Book Description:
|
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will...
More Description
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.
- Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research
- Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms
- Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment